Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rigosertib - Traws Pharma

Next Previous
X
Search
Drug Profile

Rigosertib - Traws Pharma

Alternative Names: Estybon; Novonex; ON-01910; ON-01910-sodium; ON-01910.Na; ON-01910Na; Rigosertib sodium; SyB C-1101; SyB L-1101

Latest Information Update: 23 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onconova Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; M. D. Anderson Cancer Center; National Cancer Institute (USA); SymBio Pharmaceuticals; Thomas Jefferson University; Traws Pharma
  • Class Amino acids; Antineoplastics; Antivirals; Small molecules; Sulfones
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Microtubule protein inhibitors; Polo-like kinase 1 inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Myelodysplastic syndromes
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Myelofibrosis; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Phase I/II Adenocarcinoma
  • Preclinical COVID 2019 infections; Renal cell carcinoma
  • No development reported Chronic lymphocytic leukaemia; Head and neck cancer; Ovarian cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 23 Jun 2024 3860826- MOA study hence not captured
  • 02 Apr 2024 Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
  • 20 Dec 2023 Icahn School of Medicine at Mount Sinai in collaboration with completes phase I/II trial in Non-small cell lung cancer (Metastatic disease, Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT04263090)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top